| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
3-(Aminomethyl)phenol targets the GABA receptor as an antagonist. It also targets growth factor receptor kinase (GRK) and protein kinase C as a potent inhibitor. The compound reduces prefrontal dopamine (DA) levels, indicating interactions with dopaminergic signaling pathways. Its antimicrobial activity suggests interactions with microbial cellular components. The compound's anti-inflammatory properties indicate modulation of inflammatory pathways. Its inhibitory effects on cellular proliferation suggest interactions with cell cycle regulatory pathways. The compound's specific substitution pattern confers a distinct profile of biological activities.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that 3-(Aminomethyl)phenol acts as a GABA receptor antagonist and a potent inhibitor of growth factor receptor kinase and protein kinase C. The compound reduces prefrontal dopamine levels in cell-based assays. It exhibits antimicrobial activity against various pathogens and shows potential anti-inflammatory properties. The compound has inhibitory effects on cellular proliferation in mammalian cells. These in vitro findings support its potential applications in neurological research, antimicrobial therapy, anti-inflammatory treatment, and cancer therapy as an adjuvant. Further studies are needed to fully characterize its mechanisms of action.
|
| ln Vivo |
In vivo studies of 3-(Aminomethyl)phenol have been conducted in animal models. Studies on 2-(aminomethyl)phenols have shown that certain derivatives exhibit high activity when administered intravenously or orally in animal models. The compound's ability to reduce prefrontal dopamine levels suggests potential for in vivo evaluation in neurological and psychiatric disease models. Its antimicrobial and anti-inflammatory properties indicate potential for in vivo evaluation in infection and inflammation models. The compound's inhibitory effects on cellular proliferation suggest potential for in vivo evaluation in cancer models as an adjuvant therapy. Further research is needed to fully characterize its in vivo efficacy and safety.
|
| Enzyme Assay |
In vitro receptor binding assays for 3-(Aminomethyl)phenol typically involve testing its antagonist activity at the GABA receptor. Radioligand binding assays are performed using membrane preparations expressing the GABA receptor, with displacement of a labeled ligand measured to determine binding affinity. Kinase inhibition assays are performed to evaluate inhibition of growth factor receptor kinase and protein kinase C. Enzyme activity is measured using appropriate substrates and detection methods. For antimicrobial activity, standard disc diffusion or broth microdilution methods are employed to determine minimum inhibitory concentrations (MICs). Anti-inflammatory activity is assessed by measuring inhibition of pro-inflammatory mediator production. All assays are performed with appropriate controls.
|
| Cell Assay |
In vitro cell-based assays for 3-(Aminomethyl)phenol involve culturing mammalian cells to evaluate its effects on proliferation and signaling. Cells are treated with varying concentrations of the compound and cell viability is assessed using MTT or similar colorimetric assays. Dopamine levels are measured in neuronal cell cultures using HPLC or ELISA. GABA receptor antagonism is assessed by measuring electrophysiological responses or calcium flux. Kinase inhibition is evaluated by measuring phosphorylation of downstream targets. For antimicrobial studies, bacterial or fungal cultures are treated and cell viability is monitored. All experiments are performed in triplicate with appropriate controls to ensure statistical reliability.
|
| Animal Protocol |
In vivo animal experiments for 3-(Aminomethyl)phenol utilize rodent models to evaluate its neurological, antimicrobial, anti-inflammatory, and anticancer activities. Animals are administered the compound intravenously or orally. For neurological studies, dopamine levels are measured in brain tissue. For antimicrobial studies, infected animals are treated and pathogen load assessed. For anti-inflammatory studies, animals with induced inflammation are treated and inflammatory markers measured. For cancer studies, tumor-bearing animals are treated and tumor growth monitored. Parameters assessed include body weight, organ weights, blood biochemistry, and histopathology. Control groups receiving vehicle alone are included for comparison. All procedures comply with institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of 3-(Aminomethyl)phenol reflect its nature as a small phenolic compound. It has a molecular weight of 123.16 and the molecular formula C7H9NO. The compound has a purity of 99.34%. As a small molecule with both amine and phenol functional groups, it has moderate hydrophilicity and can cross biological membranes. The compound is expected to be metabolized through standard xenobiotic pathways in the liver, including conjugation reactions. Complete pharmacokinetic profiling including half-life, clearance, volume of distribution, and bioavailability would require further systematic studies using appropriate analytical methods such as high-performance liquid chromatography-mass spectrometry.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 3-(Aminomethyl)phenol has been evaluated in the context of its use as a research chemical. Studies on aminophenols have shown that certain derivatives exhibit activity in animal models. The compound's antimicrobial, anti-inflammatory, and antiproliferative activities suggest biological effects that should be carefully evaluated. Proper handling procedures including use of personal protective equipment are recommended when working with the compound. The compound is not approved for human therapeutic use and is intended for research purposes only. Long-term toxicity studies would be needed to fully establish its safety profile. The compound's GABA receptor antagonism suggests potential for neurological effects.
|
| References | |
| Additional Infomation |
3-(aminomethyl)phenol is an aromatic amine. It has been reported that Resida medium contains 3-(aminomethyl)phenol, and relevant data are available for reference.
3-(Aminomethyl)phenol (CAS# 73604-31-6) is also known as m-Hydroxybenzylamine. It has the molecular formula C7H9NO and a molecular weight of 123.16. The compound reduces prefrontal dopamine (DA) levels and is a GABA receptor antagonist. It is a potent inhibitor of growth factor receptor kinase and protein kinase C. The compound exhibits antimicrobial activity against various pathogens and potential anti-inflammatory properties. It has inhibitory effects on cellular proliferation in mammalian cells and is being investigated as an adjuvant therapy for cancer treatment. The compound has a purity of 99.34%. It is intended for research use only. |
| Molecular Formula |
C7H9NO
|
|---|---|
| Molecular Weight |
123.15
|
| Exact Mass |
123.068
|
| CAS # |
73604-31-6
|
| PubChem CID |
735894
|
| Appearance |
White to light brown solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
264.7±15.0 °C at 760 mmHg
|
| Melting Point |
174-176ºC
|
| Flash Point |
113.9±20.4 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.594
|
| LogP |
0.35
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
9
|
| Complexity |
85
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC(=C1)O)CN
|
| InChi Key |
JNZYADHPGVZMQK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H9NO/c8-5-6-2-1-3-7(9)4-6/h1-4,9H,5,8H2
|
| Chemical Name |
3-(aminomethyl)phenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.1202 mL | 40.6009 mL | 81.2018 mL | |
| 5 mM | 1.6240 mL | 8.1202 mL | 16.2404 mL | |
| 10 mM | 0.8120 mL | 4.0601 mL | 8.1202 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
